Furthermore, our data showthat nilotinib inhibits the p38α MAPK-MK2/MK3 signaling axisduring the inflammatory response, reducing the levels of the pro-inflammatorycytokines in myeloma cells (Figure 6E). The gene discussed is MAPKAPK3; the disease is plasma cell myeloma.